Abu Dhabi Growth Fund Invests in Orbital Therapeutics
Posted on 04/26/2023
Cambridge, MA-based Orbital Therapeutics is a company focused on RNA medicines to treat human disease. Orbital Therapeutics raised US$ 270 million in a Series A round. The Series A raise was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus (Invus Group), Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and other undisclosed investors. Abu Dhabi Growth Fund is a growth focused sovereign investment fund established in July 2021 by Abu Dhabi Developmental Holding Company PJSC (ADQ).
Orbital Therapeutics aims to expand the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement. Giuseppe Ciaramella is a Co-Founder of Orbital Therapeutics. He has more than 25 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck. He was the President and Chief Scientific Officer of Beam Therapeutics Inc.
